Omalizumab biosimilar - Kashiv BioSciences
Alternative Names: ADL-018; AVT-23Latest Information Update: 14 Oct 2025
At a glance
- Originator Adello Biologics
- Developer Alvotech; Amneal Pharmaceuticals; Kashiv BioSciences
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists; Immunosuppressants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Asthma
Highest Development Phases
- Preregistration Asthma; Chronic urticaria; Food hypersensitivity; Rhinosinusitis
Most Recent Events
- 06 Oct 2025 The European Medicines Agency accepts Marketing Authorization Application for Omalizumab biosimilar for Rhinosinusitis, Asthma and Chronic-urticaria for review
- 06 Oct 2025 Preregistration for Asthma in European Union (SC)
- 06 Oct 2025 Preregistration for Chronic-urticaria in European Union (SC)